Trial Profile
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms ABRAZO
- Sponsors BioMarin Pharmaceutical; Medivation; Pfizer
- 28 May 2020 Results (n=369) characterizing the relationship between talazoparib exposure and the most common grade > 3 hematopoietic adverse events (AEs) leading to dose modification pooled from the phase 2 (ABRAZO) and phase 3 (EMBRACA) trials published in the Journal of Clinical Pharmacology
- 14 Dec 2019 Results (n=494) of pooled analysis of five trials (EMBRACA, NCT01945775; ABRAZO, NCT02034916; NCT01286987, NCT03042910 & NCT02921919) assessing safety of talazoparib in patients with avanced breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium.
- 06 Sep 2019 Results of population pharmacokinetics of talazoparib in patients with advanced cancer published in the Journal of Clinical Pharmacology